MDHearing VoltMax vs Otofonix Encore

The MDHearing VoltMax is a behind-the-ear OTC hearing aid priced at $699, earning a B grade with a SoundScore of 3.0/5 in our lab testing. This mid-priced device ranks #62 of 65 in the OTC Hearing Aid category, placing it in the bottom portion of tested products. In our standardized testing, the VoltMax demonstrates excellent feedback handling at 5.0/5, scoring 0.46 points above the category average. This means users are unlikely to experience whistling or squealing during typical wear. However, speech performance presents significant challenges—speech in quiet scores a low 1.9/5 (0.93 points below average), while speech in noise scores 1.0/5 (0.48 points below average). These results suggest limited benefit for understanding conversation in both calm and challenging listening environments. Music streaming is a notable weakness, scoring 0.0/5 and falling 1.92 points below the category average. Users who prioritize streaming audio content from their phones should consider alternatives. Own-voice comfort is mixed at 2.4/5, roughly matching the category average. At this price point, several alternatives offer substantially stronger performance. Devices like the Yeasound RIC800 and Sony CRE-E10 score above 4.5/5 at similar or lower prices. The VoltMax may appeal to users who prioritize feedback-free wear and basic amplification with rechargeable convenience, but those seeking stronger speech clarity should explore higher-performing options in this price range.

The Otofonix Encore is a behind-the-ear prescription hearing aid priced at $295, placing it in the budget tier of the prescription category. In our lab testing, it earned a C grade with a SoundScore of 2.7/5, ranking 35th out of 36 prescription hearing aids tested. Sound performance presents significant challenges across most metrics. Speech clarity scores are low in both quiet (1.0/5) and noisy environments (1.0/5), falling 2.32 and 0.96 points below category averages respectively. Music streaming capability is essentially absent at 0.0/5, and own-voice comfort is notably limited at 0.1/5 in the tuned configuration—2.65 points below the category average. The one bright spot is feedback handling, which scores an excellent 4.7/5. While this falls just 0.01 points below the category average, it represents strong absolute performance that should minimize whistling issues during daily use. This device runs on disposable batteries. At this price point, shoppers should be aware that the RxEars Rxi offers substantially better sound performance (4.09/5) in the same price range. The Otofonix Encore may suit budget-conscious consumers who prioritize feedback stability over speech clarity and streaming features, but our testing suggests most users would benefit from considering higher-performing alternatives within this price tier.